Full Press Release Details
Medical Conferences Exhibit at AAD 2025 March 7 - 11 with select meetings to follow KOL podium presentations 2. Educational Speaker Programs Utilize KOLs within each territory to educate providers about Emrosi 3. Direct Promotion Direct promotion will begin in early April Sales representatives will have product samples and promotional materials at launch e - Sampling will also be available for white space 4.
Source: Symphony Healthcare Metys Data 2. Journal of the American Academy of Dermatology Volume 82, Issue 2 , February 2020, Pages 336 - 34 Mirvaso (Brimonidine Tartrate) Rhofade (Oxymetazoline HCL) ORAL ROSACEA TREATMENTS: Oracea (doxycycline 40mg) is the only approved oral treatment option currently indicated for rosacea - For treatment of only inflammatory lesions (papules and pustules) of rosacea According to a 2020 paper in JAAD, " Combination therapy with topical and oral agents has become a common treatment option for patients with moderate or severe rosacea presenting with diverse signs and symptoms." 2 Prescriptions 16 | 2025 Journey Medical Corporation.
P - values indicate highly significant results against both comparators. *All statistical tests were two - sided, with =0.05 as level of significance Emrosi Demonstrated Superior Efficacy Over Oracea a nd Placebo IGA Treatment Success and Inflammatory Lesion Count Reduction IGA Treatment Success - Week 16 (Pooled Data) Inflammatory Lesion Absolute Change - Week 16 (Pooled Data) P<0.001 * - 19 - 14.8 - 11.3 Emrosi N=245 Oracea N=246 Placebo N=162 Lesion Count Change P<0.001 * 11 | 2025 Journey Medical Corporation.
Minocycline has a lower Cmax and levels in the blood throughout the day compared to doxycycline at the same dose. Blood is not the site of action in rosacea and so the drug is not needed to be there. Lower levels of drug in the blood are generally known to correlate with safety. Emrosi - A Novel Minocycline Formulation Beneficial Pharmacokinetic Profile 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 0 2 4 6 8 10 12 14 16 18 20 22 24 Doxy 40 mg Mino 20 mg Mino 40 mg Day=21 DAY 21 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 0 2 4 6 8 10 12 14 16 18 20 22 24 Doxy 40 mg Mino 20 mg Mino 40 mg Day=21 UNIQUE PRODUCT FORMULATION Minocycline Extended - Release Capsule 40mg (Once daily oral capsule) Emrosi was developed using Multiple Unit Pellet System technology, which combines Immediate Release (25%) and Extended Release (75%) minocycline pellets for uniform drug release.
R. (2016). Most people with psoriasis or rosacea are not being treated: a large population st udy . Dermatology Online Journal, 22(7). 2. Barakji YA, R nnstad ATM, Christensen MO, Zachariae C, Wienholtz NKF, Halling AS, Maul JT, Thomsen SF, Egeberg A, Thyssen JP. Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta - analysis.
Of patients with rosacea 3 : 90% said their condition lowered their self - confidence and self - esteem 41% said it caused them to avoid public contact or cancel social engagements 88% with severe symptoms said it adversely affected their professional interactions 51% said they missed work because of their condition 1. Wehausen , B., Hill, D. E, & Feldman, S.
In addition, projections, estimates and assumptions relating to the Company's and its industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, thos e d escribed above, that could cause future performance to differ materially from the Company's expressed projections, estimates and assumptions or those provided by third parties. 3 | 2025 Journey Medical Corporation.
The Company's ma nagement estimates are derived from third - party sources, publicly available information, the Company's knowledge of its industry and assumptions based on such information and knowledge. The Company's management estimates have not been verified b y a ny independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such informat ion .
MARKET & INDUSTRY DATA Projections, estimates, industry data and information contained in this presentation, including the size of and growth in key en d markets, are based on information from third - party sources and management estimates. Although the Company believes that its third party - sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources.
TRADEMARKS This confidential presentation may contain trademarks, service marks, trade names and copyrights of other companies, which ar e t he property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM, or symbols, but the Company will assert, to th e fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward - looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be req uir ed by law, and we claim the protection of the safe harbor for forward - looking statements contained in the Private Securities Litigation Reform Act of 1995.
Forward - looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, opera tin g results, financial condition and stock price. Factors that could cause actual results to differ materially from those curre ntl y anticipated include: the fact that our products and product candidates are subject to time and cost intensive regulation and cli nical testing and as a result, may never be successfully developed or commercialized; a substantial portion of our sales deri ve from products that may become subject to third - party generic competition, the introduction of new competitor products, or an inc rease in market share of existing competitor products, any of which could have a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or ad ministrative or executive action may have on our operations; our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results; competition co uld limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products; the risk that our products do not achieve broad market acceptance, including by government and third - party payo rs; our reliance third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in - license products and integrate them into our operations, at which we may be unsuccessful; the dependence of the su ccess of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product, Emrosi , and any future product candidates that we may develop, in - license or acquire; clinical drug development is very expensive, time cons uming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; our competitors could develop an d commercialize products similar or identical to ours; risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products; our business and operations wou ld suffer in the event of computer system failures, cyber - attacks, or deficiencies in our or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major public health issues, epidemics or p and emics on our product revenues and any future clinical trials; our potential need to raise additional capital; Fortress contro ls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other risks described i n P art I, Item 1A, "Risk Factors," in our Annual Report on Form 10 - K for the year ended December 31, 2023, subsequent Reports on Form 10 - Q, and our other filings we make with the SEC.
As used below and throughout this press release, the words "the Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but are not lim ite d to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. The words "anticipate," "believe," "estimate," "may," "expect," "will," "could," "project," "intend " a nd similar expressions are generally intended to identify forward - looking statements.